Evaxion, a clinical-stage TechBio company using AI to develop vaccines, will announce its first quarter 2026 financial results and provide a business update on May 7, 2026, before Nasdaq opens. The company will host a conference call and webcast to present the results and answer questions. Evaxion's AI-Immunology™ platform focuses on creating novel vaccine candidates for cancer and infectious diseases, aiming to address significant medical needs. Investors and interested parties can register to join the live event or access the webcast recording afterward on the company's website.
Taco Bell Canada introduced two new menu items: Crispy Chicken Nuggets with a Jalapeño Honey Mustard sauce, and Mountain Dew Baja Midnight, the first new Mountain Dew Baja Blast flavor in over 20 years. The nuggets feature all-white meat with Mexican...
VERAXA Biotech updated on its progress in developing novel cancer therapies using its proprietary BiTAC platform, focusing on conditionally active T cell engagers and bispecific antibody-drug conjugates. The company plans to prioritize investment in ...
Nexans and Hydro have agreed on a five-year contract for about 85,000 tonnes of low-carbon aluminium wire rod to support Europe's electricity grid modernization. This aluminium, produced using 100% renewable energy in Norway, will help reduce carbon ...
Nexans and Hydro have agreed on a five-year supply contract for about 85,000 tons of low-carbon aluminum wire rod to support the modernization and decarbonization of Europe's electrical grid. The aluminum, produced in Norway using 100% renewable ener...
Scilex Holding Company announced a binding term sheet with Kazakhstan-based iHolding Group LLP for a $100 million investment, purchasing about 6.67 million shares at $15 each. This funding aims to support Scilex's strategic growth in healthcare, prod...
